Good result for malaria vaccine trial

Share
Friday, 7 June, 2013
BK-SE36 - impact on malaria

A Ugandan trial of a malaria vaccine based on the BK-SE36 antigen reduced the incidence of heavy parasitaemia with fever by about 60% in 6-20 year olds (Palacpac et al 2013). The only side effect was local induration at the inoculation site in >90% of subjects. Two doses of 1 ml were given subcutaneously 3 weeks apart. A 0.5 ml dose was less effective.

References

Palacpac et al. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. PLoS One 2013;8(5):e64073.

Trial registration: here.

Posted by Rick Speare